EQS-Adhoc
LifeWatch AG: Verwaltungsrat von LifeWatch empfiehlt verbesserte Offerte von BioTelemetry zur Annahme - Seite 2
Für weitere Informationen: siehe www.lifewatch.com.
E-Mail Alert: Um regelmässig die neusten Informationen zu LifeWatch zu erhalten und Unterlagen anzufordern, registrieren Sie sich bitte unter https://www.lifewatch.com/Investor-Relations/Alert-Service.html.
Zu BioTelemetry
BioTelemetry, Inc., früher als CardioNet bekannt, ist ein führendes Unternehmen im Bereich kabelloser Medizinaltechnologie. Der Fokus liegt auf der Bereitstellung von Gesundheitsdaten zur
Verbesserung der Lebensqualität sowie zur Reduktion der Gesundheitskosten. Das Unternehmen bietet zurzeit Herzüberwachungs-Dienstleistungen an und produziert Geräte mit einem primären Fokus auf die
Herzüberwachung sowie zentralisierte Dienstleistungen für Herzlaboratorien.
Für weitere Informationen: siehe www.biotelinc.com.
Lesen Sie auch
Cautionary Statement Regarding Forward-Looking Satements
This document includes certain forward-looking statements regarding, among other things, statements about both, LifeWatch's and BioTelemetry's beliefs and expectations, statements about
BioTelemetry's proposed acquisition of LifeWatch AG, including the timing and success of the tender offer and expectations regarding the growth and success of the combined entity. These statements
may be identified by words such as "expect," "anticipate," "estimate," "intend," "plan," "believe," "promises", "projects," and other words and terms of similar meaning. Such forward-looking
statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of these expectations, and could cause
actual outcomes and results to differ materially from current expectations. Factors that may materially affect such forward-looking statements include: BioTelemetry's ability to successfully
complete the tender offer for LifeWatch's shares or realize the anticipated benefits of the transaction; and the failure of any of the conditions to BioTelemetry's tender offer to be satisfied. For
further details and a discussion of these and other risks and uncertainties, please see BioTelemetry's public filings with the Securities and Exchange Commission, including the company's latest
periodic reports on Form 10-K and 10-Q respectively LifeWatch's past press releases, reports and other information posted on LifeWatch's website. Readers are cautioned not to put undue reliance on
forward-looking statements, which reflect only opinions as of the date of this press release. BioTelemetry and LifeWatch do not undertake, and specifically disclaim, any obligation to publicly
update or amend any forward-looking statement, whether as a result of new information, future events, or otherwise.